Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS1 | P23219 | 4/20 | 0.41 |
| ▸ | PTGS2 | P35354 | 4/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | ACE | P12821 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | PKM | P14618 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | APEX1 | P27695 | 2/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | FABP3 | P05413 | 1/20 | 0.33 |
| ▸ | FABP4 | P15090 | 1/20 | 0.33 |
| ▸ | FABP5 | Q01469 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 2/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17325350 | 1.00 | PTGS1 (0.41) | PTGS1PTGS2MAPK1ACEALDH1A1 | |
| SCHEMBL18402748 | 0.89 | PTGS1 (0.46) | PTGS1PTGS2MAPK1ALDH1A1MEN1 | |
| SCHEMBL12629192 | 0.86 | PTGS1 (0.56) | PTGS1PTGS2MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL26312049 | 0.86 | PTGS1 (0.56) | PTGS1PTGS2MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL18523565 | 0.85 | KDM4E (0.36) | PTGS1PTGS2MAPK1SMN1; SMN2KDM4E | |
| SCHEMBL25148661 | 0.84 | CA1 (0.34) | MAPK1ALDH1A1 | |
| SCHEMBL22843961 | 0.82 | PTGS1 (0.32) | PTGS1PTGS2KDM4E | |
| SCHEMBL23181699 | 0.81 | PTGS1 (0.36) | PTGS1PTGS2MAPK1 | |
| SCHEMBL18930109 | 0.80 | PTGS1 (0.40) | PTGS1PTGS2MAPK1ACEALDH1A1 | |
| SCHEMBL14554023 | 0.80 | MAPK1 (0.36) | PTGS1PTGS2MAPK1ACEALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220387615-A1 | COMPOSITIONS COMPRISING ENZYME CLEAVABLE LINKER PLATFORMS AND CONJUGATES THEREOF | DANMARKS TEKNISKE UNIVERSITET (DK) | 2022-12-08 | — | — | US | disclosed |
| US-20220023437-A1 | HUMANIZED ANTI-CD79B ANTIBODIES AND IMMUNOCONJUGATES AND METHODS OF USE | GENENTECH, INC. (US) | 2022-01-27 | — | — | US | disclosed |
| US-20210369855-A1 | CONJUGATION OF A CYTOTOXIC DRUG WITH BIS-LINKAGE | HANGZHOU DAC BIOTECH CO., LTD. (CN) | 2021-12-02 | — | — | US | disclosed |
| EP-2111872-B1 | HYDROGEL CONJUGATES | ASCENDIS PHARMA GMBH (DE) | 2020-12-23 | — | — | EP | disclosed |
| US-10265291-B2 | Disulfur bridge linkers for conjugation of a cell-binding molecule | HANGZHOU DAC BIOTECH CO., LTD. (CN) | 2019-04-23 | — | — | US | disclosed |
| US-20170049906-A1 | TRANSLOCATION OF NON-NATURAL CHEMICAL ENTITIES THROUGH ANTHRAX PROTECTIVE ANTIGEN PORE | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2017-02-23 | — | — | US | disclosed |
| EP-3085388-A1 | HYPERBRANCHED POLYMER CONJUGATES VIA NON-ENZYMATIC CLEAVABLE LINKER | Ascendis Pharma Growth Disorders Division A/S (DK) | 2016-10-26 | — | — | EP | disclosed |
| EP-2090323-B1 | Hyperbranched polymer conjugates via non-enzymatic cleavable linker | ASCENDIS PHARMA GROWTH DISORDERS DIVISION AS (DK) | 2016-07-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220023437-A1 | HUMANIZED ANTI-CD79B ANTIBODIES AND IMMUNOCONJUGATES AND METHODS OF USE | CD99, CD79B, CD47 | PTGS1 4090/4885PTGS2 3843/4885MAPK1 4816/4885 |
| US-20210369855-A1 | CONJUGATION OF A CYTOTOXIC DRUG WITH BIS-LINKAGE | CD4, MCL1, CCNB1 | PTGS1 3336/4885PTGS2 4312/4885MAPK1 1789/4885 |
| US-20220387615-A1 | COMPOSITIONS COMPRISING ENZYME CLEAVABLE LINKER PLATFORMS AND CONJUGATES THEREOF | ADAM17, ADAM8, ADAM33 | PTGS1 3550/4885PTGS2 3746/4885MAPK1 3951/4885 |
| US-10265291-B2 | Disulfur bridge linkers for conjugation of a cell-binding molecule | CD74, CD2, EPCAM | PTGS1 3243/4885PTGS2 3324/4885MAPK1 3649/4885 |
| US-20170049906-A1 | TRANSLOCATION OF NON-NATURAL CHEMICAL ENTITIES THROUGH ANTHRAX PROTECTIVE ANTIGEN PORE | ANTXR2, SLC47A2, SLC47A1 | PTGS1 1438/4885PTGS2 1069/4885MAPK1 3351/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.